SPOTLIGHT: BMS selling off ConvaTec unit for $4.1B

Bristol-Myers Squibb continues to off-load parts of its business that aren't directly related to its beef-up-biopharma strategy: the company has agreed to sell its wound and ostomy care division ConvaTec to a private equity partnership for $4.1 billion. Release | Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.